The clinical effect of FEM-102 on dryness of mouth

• Published in: Japanese Journal of Oral and Maxillofacial Surgery Vol. 34; no. 2; pp. 376 - 388
• Main Authors: SHIMIZU, Yasutomo, HYO, Yukitada, SUNAGAWA, Hideki, ONO, Takatoki, YOSHITAKE, Kazusada, ISHIKAWA, Hidetoshi, SATO, Ichiro, SATO, Takumi, KIMURA, Satoru, FUKUI, Haruhide, KIMURA, Toji
• Format: Journal Article
• Language: English
• Published: Japanese Society of Oral and Maxillofacial Surgeons 1988
• Subjects: anethole trithione; dryness of mouth; salivation
• ISSN: 0021-5163; 2186-1579
• DOI: 10.5794/jjoms.34.376

In order to invcstigate the clinical effect of FEM-102 (each tablet contains 12.5 mg of Anethole Trithione) on dryness of mouth due to Xerostomia, Sjögren's syndrome and radiotherapy, two tablets of FEM-102 were administered orally t.i.d.(75 mg of Anethole Trithione/day) during 2-12 weeks. The results were as follows: 1. The efficacy on dryness of mouth was evaluated on the basis of objective findings, subjective symptoms and test of saliva and salivation.The rate of effectiveness (above effective) in Xerostomia, Sjögren's syndrome and post-radiotherapy were 72.2% (26 cases/36 cases), 42.9% (3 cases/7 cases) and 33.3% (2 cases/6 cases), respectively. 2. Increase in salivation was recognized in the patients with Xerostomia and Sjögren's syndrome after administration of FEM-102. 3. As for the adverse reactions, no remarkable finding was obtained, except digestive-tract symptoms such as break wind, flatulence and sensation of abdominal distension in 11 cases.